Edoardo Mannucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2279428/publications.pdf

Version: 2024-02-01

434 papers

22,866 citations

4388 86 h-index 126 g-index

452 all docs

452 docs citations

times ranked

452

19909 citing authors

#	Article	IF	CITATIONS
1	Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology, 2011, 165, 687-701.	3.7	376
2	Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology, 2013, 168, 829-843.	3.7	343
3	Testosterone and Metabolic Syndrome: A Meta-Analysis Study. Journal of Sexual Medicine, 2011, 8, 272-283.	0.6	310
4	Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2011, 13, 221-228.	4.4	309
5	Type 2 diabetes mellitus and testosterone: a meta-analysis study. Journal of Developmental and Physical Disabilities, 2011, 34, 528-540.	3.6	299
6	Depression as a Risk Factor for Diabetes. Journal of Clinical Psychiatry, 2013, 74, 31-37.	2.2	286
7	Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects. Diabetes Care, 2001, 24, 489-494.	8.6	281
8	Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2014, 13, 1327-1351.	2.4	260
9	Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. Diabetes Care, 2011, 34, 2474-2476.	8.6	241
10	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	11.4	231
11	Dipeptidyl peptidaseâ€4 inhibitors and cardiovascular risk: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 112-120.	4.4	229
12	Psychobiologic Correlates of the Metabolic Syndrome and Associated Sexual Dysfunction. European Urology, 2006, 50, 595-604.	1.9	223
13	Efficacy and safety of sodium glucose coâ€transportâ€2 inhibitors in type 2 diabetes: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 457-466.	4.4	217
14	Diagnostic Crossover and Outcome Predictors in Eating Disorders According to DSM-IV and DSM-V Proposed Criteria: A 6-Year Follow-Up Study. Psychosomatic Medicine, 2011, 73, 270-279.	2.0	206
15	Eating disorders in patients with Type 1 diabetes: A meta-analysis. Journal of Endocrinological Investigation, 2005, 28, 417-419.	3.3	203
16	Cardiovascular safety of sulfonylureas: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 938-953.	4.4	201
17	Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2011, 27, 57-64.	1.9	198
18	Testosterone Supplementation and Sexual Function: A Meta-Analysis Study. Journal of Sexual Medicine, 2014, 11, 1577-1592.	0.6	195

#	Article	IF	Citations
19	Longâ€acting insulin analogues vs. NPH human insulin in type 1 diabetes. A metaâ€analysis. Diabetes, Obesity and Metabolism, 2009, 11, 372-378.	4.4	190
20	Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Journal of Developmental and Physical Disabilities, 2009, 32, 587-598.	3.6	189
21	Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Research and Clinical Practice, 2008, 81, 184-189.	2.8	186
22	DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Advances in Therapy, 2012, 29, 14-25.	2.9	185
23	Autologous Cell Therapy for Peripheral Arterial Disease. Circulation Research, 2017, 120, 1326-1340.	4.5	181
24	Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients. Diabetes Care, 2008, 31, 199-203.	8.6	177
25	Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Research and Clinical Practice, 2013, 99, 98-104.	2.8	177
26	Sulphonylureas and cancer: a case–control study. Acta Diabetologica, 2009, 46, 279-284.	2.5	171
27	THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. European Journal of Endocrinology, 2016, 174, R99-R116.	3.7	171
28	Structured interview on erectile dysfunction (SIEDY©): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. International Journal of Impotence Research, 2003, 15, 210-220.	1.8	170
29	Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 604-612.	2.6	168
30	Glycaemic efficacy of glucagonâ€like peptideâ€l receptor agonists and dipeptidyl peptidaseâ€l inhibitors as addâ€on therapy to metformin in subjects with type 2 diabetesâ€"a review and meta analysis. Diabetes, Obesity and Metabolism, 2012, 14, 762-767.	4.4	168
31	Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 689-697.	2.6	167
32	Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. European Urology, 2017, 72, 1000-1011.	1.9	163
33	Quality of life and overweight. Addictive Behaviors, 1999, 24, 345-357.	3.0	161
34	Psycho-Biological Correlates of Rapid Ejaculation in Patients Attending an Andrologic Unit for Sexual Dysfunctions. European Urology, 2004, 46, 615-622.	1.9	158
35	Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. International Journal of Impotence Research, 2006, 18, 190-197.	1.8	158
36	Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 224-235.	2.6	158

#	Article	IF	CITATIONS
37	Safety issues with glucagonâ€like peptideâ€l receptor agonists (pancreatitis, pancreatic cancer and) Tj ETQq1 1 2017, 19, 1233-1241.	0.784314 4.4	rgBT /Overl 155
38	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 38-47.	4.4	151
39	A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 231-241.	8.6	149
40	Correlations between binge eating and emotional eating in a sample of overweight subjects. Appetite, 2009, 53, 418-421.	3.7	148
41	Testosterone supplementation and body composition: results from a meta-analysis of observational studies. Journal of Endocrinological Investigation, 2016, 39, 967-981.	3.3	147
42	Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women. Diabetes Care, 2007, 30, 1241-1247.	8.6	144
43	Factors affecting spermatogenesis upon gonadotropinâ€replacement therapy: a metaâ€analytic study. Andrology, 2014, 2, 794-808.	3.5	144
44	Screening for binge eating disorder in obese outpatients. Comprehensive Psychiatry, 2000, 41, 111-115.	3.1	139
45	Eating Disorders and Body Image Disturbances among Ballet Dancers, Gymnasium Users and Body Builders. Psychopathology, 2003, 36, 247-254.	1.5	139
46	Different Testosterone Levels Are Associated with Ejaculatory Dysfunction. Journal of Sexual Medicine, 2008, 5, 1991-1998.	0.6	137
47	Testosterone Partially Ameliorates Metabolic Profile and Erectile Responsiveness to PDE5 Inhibitors in an Animal Model of Male Metabolic Syndrome. Journal of Sexual Medicine, 2009, 6, 3274-3288.	0.6	133
48	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European Journal of Endocrinology, 2009, 160, 909-917.	3.7	132
49	Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 337-353.	4.7	130
50	Obesity and late-onset hypogonadism. Molecular and Cellular Endocrinology, 2015, 418, 120-133.	3.2	128
51	Fluoxetine and Fluvoxamine Combined with Individual Cognitive-Behaviour Therapy in Binge Eating Disorder: A One-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2001, 70, 298-306.	8.8	124
52	Hypoprolactinemia: A New Clinical Syndrome in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 1457-1466.	0.6	123
53	Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Journal of Developmental and Physical Disabilities, 2011, 34, 41-48.	3.6	121
54	Penile Doppler Ultrasound in Patients with Erectile Dysfunction (ED): Role of Peak Systolic Velocity Measured in the Flaccid State in Predicting Arteriogenic ED and Silent Coronary Artery Disease. Journal of Sexual Medicine, 2008, 5, 2623-2634.	0.6	120

#	Article	IF	CITATIONS
55	Effect of Hyperprolactinemia in Male Patients Consulting for Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1485-1493.	0.6	116
56	ANDROTEST©: A Structured Interview for the Screening of Hypogonadism in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2006, 3, 706-715.	0.6	115
57	Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. Journal of Sexual Medicine, 2018, 15, 1260-1271.	0.6	115
58	Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. International Journal of Cardiology, 2017, 243, 86-90.	1.7	114
59	Male Sexuality and Cardiovascular Risk. A Cohort Study in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1918-1927.	0.6	113
60	Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 1259-1269.	0.6	112
61	Low Testosterone is Associated with an Increased Risk of MACE Lethality in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1557-1564.	0.6	111
62	Liver enzymes and risk of diabetes and cardiovascular disease: Results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism: Clinical and Experimental, 2008, 57, 387-392.	3 . 4	109
63	Fat boosts, while androgen receptor activation counteracts, BPHâ€associated prostate inflammation. Prostate, 2013, 73, 789-800.	2.3	109
64	Low Levels of Androgens in Men with Erectile Dysfunction and Obesity. Journal of Sexual Medicine, 2008, 5, 2454-2463.	0.6	105
65	Psycho-biological correlates of hypoactive sexual desire in patients with erectile dysfunction. International Journal of Impotence Research, 2004, 16, 275-281.	1.8	104
66	Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 1997-2003.	8.6	102
67	The ageâ€related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Journal of Developmental and Physical Disabilities, 2009, 32, 720-728.	3.6	101
68	Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetologica, 2014, 51, 91-101.	2.5	100
69	ORIGINAL RESEARCHâ€"ENDOCRINOLOGY: NCEP-ATPIII-Defined Metabolic Syndrome, Type 2 Diabetes Mellitus, and Prevalence of Hypogonadism in Male Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1038-1045.	0.6	99
70	Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients. Stroke, 2007, 38, 1154-1160.	2.0	98
71	Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes, 2011, 60, 644-651.	0.6	98
72	Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabetic Medicine, 2000, 17, 713-719.	2.3	97

#	Article	IF	Citations
73	Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 2011, 34, 129-131.	8.6	97
74	Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?. Diabetes Care, 2013, 36, S259-S263.	8.6	96
75	Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetologica, 2010, 47, 77-81.	2.5	95
76	How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian Journal of Andrology, 2012, 14, 251-259.	1.6	95
77	Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. International Journal of Obesity, 2006, 30, 1132-1137.	3.4	93
78	Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes/Metabolism Research and Reviews, 2007, 23, 479-484.	4.0	93
79	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials. Experimental Diabetes Research, 2011, 2011, 1-10.	3.8	93
80	Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Research and Clinical Practice, 2017, 130, 53-60.	2.8	93
81	Risk Factors Associated with Primary and Secondary Reduced Libido in Male Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 1074-1089.	0.6	91
82	Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. Journal of Sexual Medicine, 2018, 15, 820-838.	0.6	91
83	Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes/Metabolism Research and Reviews, 2006, 22, 477-482.	4.0	90
84	Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. Journal of Endocrinological Investigation, 2007, 30, RC26-RC30.	3.3	90
85	Aging and pathogenesis of erectile dysfunction. International Journal of Impotence Research, 2004, 16, 395-402.	1.8	89
86	Relationship between leptin and oestrogens in healthy women. European Journal of Endocrinology, 1998, 139, 198-201.	3.7	88
87	Psycho-Biological Correlates of Free-Floating Anxiety Symptoms in Male Patients With Sexual Dysfunctions. Journal of Andrology, 2006, 27, 86-93.	2.0	88
88	Rosiglitazone and Risk of Cancer. Diabetes Care, 2008, 31, 1455-1460.	8.6	87
89	Organic, Relational and Psychological Factors in Erectile Dysfunction in Men with Diabetes Mellitus. European Urology, 2004, 46, 222-228.	1.9	86
90	Serum PSA as a Predictor of Testosterone Deficiency. Journal of Sexual Medicine, 2013, 10, 2518-2528.	0.6	86

#	Article	IF	CITATIONS
91	Psychobiological Correlates of Delayed Ejaculation in Male Patients With Sexual Dysfunctions. Journal of Andrology, 2006, 27, 453-458.	2.0	84
92	Assessment of the Relational Factor in Male Patients Consulting for Sexual Dysfunction: The Concept of Couple Sexual Dysfunction. Journal of Andrology, 2006, 27, 795-801.	2.0	83
93	Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 48-56.	4.4	83
94	ORIGINAL RESEARCHâ€"ENDOCRINOLOGY: A Comparison of NCEP-ATPIII and IDF Metabolic Syndrome Definitions with Relation to Metabolic Syndrome-Associated Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 789-796.	0.6	81
95	Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?. Journal of Developmental and Physical Disabilities, 2009, 32, 431-441.	3.6	81
96	Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, 2014, 103, 269-275.	2.8	81
97	How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. Journal of Endocrinological Investigation, 2016, 39, 473-484.	3.3	81
98	Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Advances in Therapy, 2012, 29, 736-746.	2.9	80
99	The Diabetic Person Beyond a Foot Ulcer. Journal of the American Podiatric Medical Association, 2008, 98, 130-136.	0.3	79
100	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	79
101	The Effect of Statin Therapy on Testosterone Levels in Subjects Consulting for Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1547-1556.	0.6	78
102	Erectile dysfunction and central obesity: an Italian perspective. Asian Journal of Andrology, 2014, 16, 581.	1.6	78
103	The impotent couple: low desire. Journal of Developmental and Physical Disabilities, 2005, 28, 46-52.	3.6	77
104	Shortâ€acting insulin analogues vs. regular human insulin in type 2 diabetes: a metaâ€analysis. Diabetes, Obesity and Metabolism, 2009, 11, 53-59.	4.4	77
105	Pioglitazone and cardiovascular risk. A comprehensive metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2008, 10, 1221-1238.	4.4	76
106	Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 19-36.	2.5	75
107	Association between Psychiatric Symptoms and Erectile Dysfunction. Journal of Sexual Medicine, 2008, 5, 458-468.	0.6	74
108	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Therapy, 2015, 6, 239-256.	2.5	74

#	Article	IF	CITATIONS
109	Hypogonadism and metabolic syndrome. Journal of Endocrinological Investigation, 2011, 34, 557-67.	3.3	74
110	Clinical and psychological correlates of health-related quality of life in obese patients. Health and Quality of Life Outcomes, 2010, 8, 90.	2.4	72
111	Sexual dysfunction in subjects treated with inhibitors of 5αâ€reductase for benign prostatic hyperplasia: a comprehensive review and metaâ€analysis. Andrology, 2017, 5, 671-678.	3.5	72
112	Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetologica, 2019, 56, 973-980.	2.5	72
113	Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 2154-2159.	8.6	71
114	The Association Between Varicocele, Premature Ejaculation and Prostatitis Symptoms: Possible Mechanisms. Journal of Sexual Medicine, 2009, 6, 2878-2887.	0.6	71
115	Prevalence of Endocrine and Metabolic Disorders in Subjects with Erectile Dysfunction: A Comparative Study. Journal of Sexual Medicine, 2015, 12, 956-965.	0.6	71
116	Eating behavior in obese patients with and without type 2 diabetes mellitus. International Journal of Obesity, 2002, 26, 848-853.	3.4	70
117	Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. Molecular and Cellular Endocrinology, 2014, 384, 143-154.	3.2	70
118	Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. International Journal of Obesity, 2008, 32, 185-191.	3.4	69
119	Firstâ€generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and metaâ€analysis. Andrology, 2016, 4, 1002-1009.	3.5	69
120	Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochemical and Biophysical Research Communications, 2003, 310, 28-31.	2.1	68
121	Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Science and Technology, 2018, 12, 183-189.	2.2	68
122	SIEDY Scale 3, a New Instrument to Detect Psychological Component in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2012, 9, 2017-2026.	0.6	66
123	Cardiac safety profile of rosiglitazone. International Journal of Cardiology, 2010, 143, 135-140.	1.7	65
124	Comparison of individual and group cognitive behavioral therapy for binge eating disorder. A randomized, three-year follow-up study. Appetite, 2010, 55, 656-665.	3.7	65
125	Sexual dysfunction in subjects with Klinefelter's syndrome. Journal of Developmental and Physical Disabilities, 2010, 33, 574-580.	3.6	64
126	Predictors of response to dipeptidyl peptidaseâ€4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research and Reviews, 2011, 27, 362-372.	4.0	64

#	Article	IF	Citations
127	Dehydroepiandrosterone Supplementation in Elderly Men: A Meta-Analysis Study of Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3615-3626.	3.6	63
128	Pulse Pressure, an Index of Arterial Stiffness, is Associated with Androgen Deficiency and Impaired Penile Blood Flow in Men with ED. Journal of Sexual Medicine, 2009, 6, 285-293.	0.6	61
129	A metaâ€nalysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2014, 16, 833-840.	4.4	61
130	Perspectives in GLP-1 Research: New Targets, New Receptors. Trends in Endocrinology and Metabolism, 2016, 27, 427-438.	7.1	61
131	Cardiometabolic Risk and Female Sexuality: Focus on Clitoral Vascular Resistance. Journal of Sexual Medicine, 2016, 13, 1651-1661.	0.6	61
132	Sociodemographic and Clinical Features of Gender Identity Disorder: An Italian Multicentric Evaluation. Journal of Sexual Medicine, 2013, 10, 408-419.	0.6	60
133	Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 933-941.	2.5	59
134	Low Diastolic Ambulatory Blood Pressure Is Associated with Greater All ause Mortality in Older Patients with Hypertension. Journal of the American Geriatrics Society, 2009, 57, 291-296.	2.6	58
135	Thyroid hormones and male sexual function. Journal of Developmental and Physical Disabilities, 2012, 35, 668-679.	3.6	58
136	Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2008, 79, 196-203.	2.8	57
137	Impairment of Couple Relationship in Male Patients with Sexual Dysfunction is Associated with Overt Hypogonadism. Journal of Sexual Medicine, 2009, 6, 2591-2600.	0.6	56
138	Different Moderators of Cognitive-Behavioral Therapy on Subjective and Objective Binge Eating in Bulimia Nervosa and Binge Eating Disorder: A Three-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2012, 81, 11-20.	8.8	56
139	Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes. Diabetes, 2016, 65, 2795-2809.	0.6	56
140	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. Journal of Endocrinological Investigation, 2008, 31, 146-152.	3.3	55
141	Longâ€term treatment with Sitagliptin, a dipeptidyl peptidaseâ€4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2â€dimethylhydrazineâ€induced rats. International Journal of Cancer, 2013, 133, 2498-2503.	5.1	55
142	Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. International Journal of Obesity, 2004, 28, 1456-1462.	3.4	54
143	Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. Journal of Endocrinological Investigation, 2017, 40, 1251-1258.	3.3	54
144	Flaccid Penile Acceleration as a Marker of Cardiovascular Risk in Men without Classical Risk Factors. Journal of Sexual Medicine, 2014, 11, 173-186.	0.6	53

#	Article	IF	Citations
145	All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes/Metabolism Research and Reviews, 2004, 20, 44-47.	4.0	52
146	Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular Diabetology, 2016, 15, 123.	6.8	52
147	Cognitive-Behavioral Therapy for Threshold and Subthreshold Anorexia Nervosa: A Three-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2010, 79, 238-248.	8.8	50
148	Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetologica, 2003, 40, 181-186.	2.5	49
149	The metabolic syndrome in treatment-seeking obese persons. Metabolism: Clinical and Experimental, 2004, 53, 435-440.	3.4	49
150	Hormonal Association and Sexual Dysfunction in Patients with Impaired Fasting Glucose: A Cross-Sectional and Longitudinal Study. Journal of Sexual Medicine, 2012, 9, 1669-1680.	0.6	49
151	Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1106-1114.	2.6	49
152	Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 639-645.	2.6	48
153	Body Mass Index Regulates Hypogonadism-Associated CV Risk: Results from a Cohort of Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 2098-2105.	0.6	48
154	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study—the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQqC	0 0.5 gBT	/Owwarlock 10 ⁻
155	National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the Flrenze-Bagno A Ripoli study. Diabetes, Obesity and Metabolism, 2008, 10, 430-435.	4.4	47
156	Cognitive-Behavioural Therapy for Bulimia nervosa and Binge Eating Disorder. Psychotherapy and Psychosomatics, 2000, 69, 287-295.	8.8	46
157	Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Journal of Developmental and Physical Disabilities, 2011, 34, 217-224.	3.6	46
158	Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. Journal of Endocrinological Investigation, 2014, 37, 477-495.	3.3	46
159	Sodiumâ€glucose coâ€ŧransporterâ€2 (SGLTâ€2) inhibitors and cancer: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2019, 21, 1871-1877.	4.4	46
160	Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 159, 107981.	2.8	46
161	Cystatin C reference values and aging. Clinical Biochemistry, 2006, 39, 658-661.	1.9	45
162	"lt Takes Two to Tango― The Relational Domain in a Cohort of Subjects with Erectile Dysfunction (ED). Journal of Sexual Medicine, 2012, 9, 3126-3136.	0.6	45

#	Article	IF	CITATIONS
163	Aggressiveness, Anger and Eating Disorders: A Review. Psychopathology, 2006, 39, 55-68.	1.5	44
164	Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Laboratory Investigation, 2008, 88, 1049-1056.	3.7	44
165	Skin autofluorescence in type 2 diabetes: Beyond blood glucose. Diabetes Research and Clinical Practice, 2008, 79, 56-60.	2.8	44
166	Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology, 2014, 2, 741-747.	3.5	44
167	Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy, 2017, 34, 1-40.	2.9	43
168	Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetologica, 2012, 49, 307-314.	2.5	42
169	Differential Effects of Testosterone and Estradiol on Clitoral Function: An Experimental Study in Rats. Journal of Sexual Medicine, 2016, 13, 1858-1871.	0.6	42
170	Restoration of Cardiomyocyte Functional Properties by Angiotensin II Receptor Blockade in Diabetic Rats. Diabetes, 2004, 53, 1927-1933.	0.6	41
171	IDF and ATPâ€III definitions of metabolic syndrome in the prediction of allâ€cause mortality in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2007, 9, 350-353.	4.4	41
172	Psychobiological Correlates of Extramarital Affairs and Differences Between Stable and Occasional Infidelity Among Men with Sexual Dysfunctions. Journal of Sexual Medicine, 2009, 6, 866-875.	0.6	41
173	Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?. Advances in Therapy, 2012, 29, 218-233.	2.9	41
174	Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology, 2013, 1, 864-871.	3.5	41
175	Short and mediumâ€term efficacy of sodium glucose coâ€transporterâ€2 (SGLTâ€2) inhibitors: A metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 1213-1222.	4.4	41
176	PCSK9 inhibitor therapy: A systematic review and metaâ€analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 903-908.	4.4	41
177	Sexual Function in Obese Women with and without Binge Eating Disorder. Journal of Sexual Medicine, 2010, 7, 3969-3978.	0.6	40
178	Childhood maltreatment in subjects with male-to-female gender identity disorder. International Journal of Impotence Research, 2011, 23, 276-285.	1.8	39
179	Characteristics of Compensated Hypogonadism in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2014, 11, 1823-1834.	0.6	39
180	Effects of a Short Educational Program for the Prevention of Foot Ulcers in High-Risk Patients: A Randomized Controlled Trial. International Journal of Endocrinology, 2015, 2015, 1-5.	1.5	39

#	Article	IF	CITATIONS
181	Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: A Meta-analysis. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 220-222.	1.2	38
182	The Relationship of Testosterone to Prostate-Specific Antigen in Men with Sexual Dysfunction. Journal of Sexual Medicine, 2010, 7, 284-292.	0.6	38
183	Hypogonadism as an additional indication for bariatric surgery in male morbid obesity?. European Journal of Endocrinology, 2014, 171, 555-560.	3.7	38
184	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. European Journal of Nutrition, 2018, 57, 679-688.	3.9	38
185	Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetologica, 2012, 49, 59-63.	2.5	37
186	Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis. Diabetes Care, 2016, 39, S196-S204.	8.6	37
187	Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 153, 138-144.	2.8	37
188	Psychobiological correlates of smoking in patients with erectile dysfunction. International Journal of Impotence Research, 2005, 17, 527-534.	1.8	36
189	Relationship between GLPâ€1 levels and dipeptidyl peptidaseâ€4 activity in different glucose tolerance conditions. Diabetic Medicine, 2010, 27, 691-695.	2.3	36
190	Relationship of Testis Size and LH Levels with Incidence of Major Adverse Cardiovascular Events in Older Men with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 2761-2773.	0.6	36
191	Trends over 8Âyears in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. Acta Diabetologica, 2015, 52, 557-571.	2.5	36
192	Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. International Journal of Cardiology, 2017, 240, 414-421.	1.7	36
193	Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 396-398.	2.6	36
194	Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2013, 29, 369-378.	1.9	35
195	Autoeroticism, Mental Health, and Organic Disturbances in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 182-191.	0.6	34
196	Glucagonâ€like peptideâ€1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated metaâ€analysis and subgroup analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 203-211.	4.4	34
197	Metformin Beyond Diabetes: New Life for an Old Drug. Current Diabetes Reviews, 2006, 2, 307-315.	1.3	33
198	Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. Journal of Endocrinological Investigation, 2019, 42, 1029-1039.	3.3	33

#	Article	IF	CITATIONS
199	Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion, 2012, 28, 715-721.	1.9	32
200	Which are the male factors associated with female sexual dysfunction (FSD)?. Andrology, 2016, 4, 911-920.	3 . 5	32
201	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and allâ€cause mortality: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1052-1056.	4.4	32
202	Isolated ambulatory hypertension is common in outpatients referred to a hypertension centre. Journal of Human Hypertension, 2004, 18, 897-903.	2.2	31
203	Glucagon-like peptide 1 (GLP-1) and metabolic diseases. Journal of Endocrinological Investigation, 2005, 28, 746-758.	3.3	31
204	Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index?. Fertility and Sterility, 2013, 99, 1872-1879.e1.	1.0	31
205	Impact of technology on glycaemic control in type 2 diabetes: A metaâ€analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes, Obesity and Metabolism, 2019, 21, 2619-2625.	4.4	31
206	Rate and Predictors of Hesitancy toward SARS-CoV-2 Vaccine among Type 2 Diabetic Patients: Results from an Italian Survey. Vaccines, 2021, 9, 460.	4.4	31
207	Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies. Vaccines, 2020, 8, 263.	4.4	30
208	Assessment of Basic Symptoms in Schizophrenia, Schizoaffective and Bipolar Disorders. Psychopathology, 1997, 30, 53-58.	1.5	29
209	The prevalence of coronary heart disease in TypeÂ2 diabetic patients in Italy: the DAI study. Diabetic Medicine, 2004, 21, 738-745.	2.3	29
210	Is Obesity a Further Cardiovascular Risk Factor in Patients with Erectile Dysfunction?. Journal of Sexual Medicine, 2010, 7, 2538-2546.	0.6	29
211	Severe Depressive Symptoms and Cardiovascular Risk in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 3477-3486.	0.6	29
212	Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. Experimental Diabetes Research, 2011, 2011, 1-6.	3.8	29
213	Understanding EMPA-REG OUTCOME. Lancet Diabetes and Endocrinology, the, 2015, 3, 929-930.	11.4	29
214	Type 1 diabetes and periodontitis: prevalence and periodontal destruction—a systematic review. Acta Diabetologica, 2020, 57, 1405-1412.	2.5	29
215	Poor Response to Alprostadil ICI Test is Associated with Arteriogenic Erectile Dysfunction and Higher Risk of Major Adverse Cardiovascular Events. Journal of Sexual Medicine, 2011, 8, 3433-3445.	0.6	28
216	Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetologica, 2017, 54, 1101-1114.	2.5	28

#	Article	IF	CITATIONS
217	Personality features of obese women in relation to binge eating and night eating. Psychiatry Research, 2013, 207, 86-91.	3.3	27
218	Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetologica, 2020, 57, 689-696.	2.5	27
219	Pulse pressure and mortality in hypertensive type 2 diabetic patients. A cohort study. Diabetes/Metabolism Research and Reviews, 2006, 22, 172-175.	4.0	26
220	Hysterical Traits are Not from the Uterus but from the Testis: A Study in Men with Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 2321-2331.	0.6	26
221	Perceived Ejaculate Volume Reduction in Patients With Erectile Dysfunction: Psychobiologic Correlates. Journal of Andrology, 2011, 32, 333-339.	2.0	26
222	Fournier's gangrene and sodiumâ€glucose coâ€transporterâ€2 inhibitors: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 272-275.	4.4	26
223	Metabolic surgery for the treatment of type 2 diabetes: A network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 1378-1387.	4.4	26
224	Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 699-704.	2.6	26
225	Comparison between different types of exercise training in patients with type 2 diabetes mellitus: A systematic review and network metanalysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1985-1992.	2.6	26
226	Treatment with Insulin Secretagogues and Cancer-Related Mortality in Type 2 Diabetic Patients A Retrospective Cohort Study. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, 184-189.	1.2	25
227	Pulse Pressure and Prediction of Incident Foot Ulcers in Type 2 Diabetes. Diabetes Care, 2009, 32, 897-899.	8.6	25
228	Priapus is Happier with Venus than with Bacchus. Journal of Sexual Medicine, 2010, 7, 2831-2841.	0.6	25
229	Diabetes and sex: from pathophysiology to personalized medicine. Internal and Emergency Medicine, 2012, 7, 215-219.	2.0	25
230	Effect of diabetes on hospitalization for ischemic stroke and related inâ€hospital mortality: a study in Tuscany, Italy, over years 2004–2011. Diabetes/Metabolism Research and Reviews, 2015, 31, 280-286.	4.0	25
231	Psychobiological Correlates of Vaginismus: An Exploratory Analysis. Journal of Sexual Medicine, 2017, 14, 1392-1402.	0.6	25
232	Effects of probiotic supplementation during pregnancy on metabolic outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108111.	2.8	25
233	Orlistat and sibutramine beyond weight loss. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 342-348.	2.6	24
234	The Identification of Prediabetes Condition with ARIC Algorithm Predicts Long-Term CV Events in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 1114-1123.	0.6	24

#	Article	IF	CITATIONS
235	Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Molecular and Cellular Endocrinology, 2015, 402, 43-50.	3.2	24
236	Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies. Acta Diabetologica, 2021, 58, 1603-1611.	2.5	24
237	Age-Related Changes in Treatment Strategies for Acute Myocardial Infarction: A Population-Based Study. Journal of the American Geriatrics Society, 2004, 52, 1355-1360.	2.6	23
238	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. American Heart Journal, 2006, 151, 1094-1100.	2.7	23
239	Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. Aging Clinical and Experimental Research, 2007, 19, 492-496.	2.9	23
240	Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. Cardiovascular Diabetology, 2009, 8, 32.	6.8	23
241	Pulse Pressure Independently Predicts Major Cardiovascular Events in Younger But Not in Older Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 247-254.	0.6	23
242	Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovascular Diabetology, 2012, 11, 151.	6.8	23
243	Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia ― The SCELTA Trial ―. Circulation Journal, 2018, 82, 1688-1698.	1.6	23
244	Sex hormoneâ€binding globulin is associated with androgen deficiency features independently of total testosterone. Clinical Endocrinology, 2018, 88, 556-564.	2.4	23
245	How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 719-726.	2.6	22
246	Group versus individual cognitive-behavioral treatment for obesity: Results after 36 months. Eating and Weight Disorders, 2007, 12, 147-153.	2.5	22
247	Dimensional Profiles of Male to Female Gender Identity Disorder: An Exploratory Research. Journal of Sexual Medicine, 2010, 7, 2487-2498.	0.6	22
248	Bone: Incretin Hormones Perceiver or Receiver?. Experimental Diabetes Research, 2012, 2012, 1-5.	3.8	22
249	Fasting and post-prandial glucose and diabetic complication. A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 591-598.	2.6	22
250	Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits. Molecular and Cellular Endocrinology, 2016, 424, 50-70.	3.2	22
251	The Role of testosterone treatment in patients with metabolic disorders. Expert Review of Clinical Pharmacology, 2021, 14, 1091-1103.	3.1	22
252	Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3243-3246.	2.6	22

#	Article	IF	Citations
253	Pharmacological treatment of acute-phase anorexia nervosa: Evidence from randomized controlled trials. Journal of Psychopharmacology, 2020, 34, 864-873.	4.0	22
254	Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. Diabetic Medicine, 1999, 16, 579-585.	2.3	21
255	Plasma Adiponectin and Hyperglycaemia in Diabetic Patients. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1131-5.	2.3	21
256	Difficulties in achieving vs maintaining erection: organic, psychogenic and relational determinants. International Journal of Impotence Research, 2005, 17, 252-258.	1.8	21
257	Winners and losers at the rosiglitazone gamble. Diabetes Research and Clinical Practice, 2008, 82, 48-57.	2.8	21
258	Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future. International Journal of Endocrinology and Metabolism, 2013, 11, 137-44.	1.0	21
259	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Advances in Therapy, 2017, 34, 1791-1814.	2.9	21
260	Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2745-2755.	2.6	21
261	Drugs for type 2 diabetes: role in the regulation of bone metabolism. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 130-4.	1.0	21
262	A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Research and Clinical Practice, 2007, 78, 132-135.	2.8	20
263	Adiponectin in outpatients with coronary artery disease: Independent predictors and relationship with heart failure. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 292-299.	2.6	20
264	Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. International Journal of Cardiology, 2017, 241, 302-310.	1.7	20
265	Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. European Neuropsychopharmacology, 2020, 32, 56-65.	0.7	20
266	Incidence and prognostic significance of hypoglycemia in hospitalized non-diabetic elderly patients. Aging Clinical and Experimental Research, 2006, 18, 446-451.	2.9	19
267	Perceived Reduced Sleep-Related Erections in Subjects with Erectile Dysfunction: Psychobiological Correlates. Journal of Sexual Medicine, 2011, 8, 1780-1788.	0.6	19
268	Adipokines as Possible New Predictors of Cardiovascular Diseases: A Case Control Study. Journal of Nutrition and Metabolism, 2012, 2012, 1-5.	1.8	19
269	Metabolic and Cardiovascular Outcomes of Fatherhood: Results from a Cohort of Study in Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2012, 9, 2785-2794.	0.6	19
270	Sexual and Cardiovascular Correlates of Male Unfaithfulness. Journal of Sexual Medicine, 2012, 9, 1508-1518.	0.6	19

#	Article	IF	CITATIONS
271	Gender-related drug effect on several markers of oxidation stress in diabetes patients with and without complications. European Journal of Pharmacology, 2015, 766, 86-90.	3.5	19
272	High Triglycerides Predicts Arteriogenic Erectile Dysfunction and Major Adverse Cardiovascular Events in Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2016, 13, 1347-1358.	0.6	19
273	Prostanoids in patients with peripheral arterial disease. Journal of Diabetes and Its Complications, 2016, 30, 161-166.	2.3	19
274	Attending Diabetes Clinics is associated with a lower all-cause mortality. A meta-analysis of observational studies performed in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 431-435.	2.6	19
275	Finger Sepsis in Two Poorly Controlled Diabetic Patients With Reuse of Lancets. Diabetes Care, 2002, 25, 1103-1103.	8.6	18
276	Amphetamine derivatives and obesity. Appetite, 2009, 52, 405-409.	3.7	18
277	HbA1c levels and all-cause mortality in type 2 diabetic patients: Epidemiological evidence of the need for personalised therapeutic targets. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 300-306.	2.6	18
278	Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics Journal, 2015, 15, 49-54.	2.0	18
279	Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1601-1608.	2.6	18
280	Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine, 2020, 69, 504-507.	2.3	18
281	Is the Third Component of Metabolic Syndrome Really Predictive of Outcomes in Type 2 Diabetic Patients?. Diabetes Care, 2006, 29, 2515-2517.	8.6	17
282	Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews, 2007, 23, 625-630.	4.0	17
283	Psychobiological Correlates of Women's Sexual Interest as Perceived by Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 2174-2183.	0.6	17
284	Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes. Advances in Therapy, 2013, 30, 190-202.	2.9	17
285	Variability of triglyceride levels and incidence of microalbuminuria in type 2 diabetes. Journal of Clinical Lipidology, 2016, 10, 109-115.	1.5	17
286	Directâ€acting antivirals for HCV treatment in older patients: A systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2019, 26, 1249-1256.	2.0	17
287	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2539-2546.	2.6	17
288	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 32-40.	2.6	16

#	Article	IF	CITATIONS
289	Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL†cells). British Journal of Pharmacology, 2008, 153, 907-914.	5.4	16
290	Metformin In Vitro and In Vivo Increases Adenosine Signaling in Rabbit Corpora Cavernosa. Journal of Sexual Medicine, 2014, 11, 1694-1708.	0.6	16
291	Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetologica, 2016, 53, 35-40.	2.5	16
292	Clinical impact of the new SIAPEC-IAP classification on the indeterminate category of thyroid nodules. Journal of Endocrinological Investigation, 2019, 42, 1-6.	3.3	16
293	Long-term interactive group education for type 1 diabetic patients. Acta Diabetologica, 2005, 42, 1-6.	2.5	15
294	Insulin Therapy and Cancer in Type 2 Diabetes. Isrn Endocrinology, 2012, 2012, 1-12.	2.0	15
295	Two Unconventional Risk Factors for Major Adverse Cardiovascular Events in Subjects with Sexual Dysfunction: Low Education and Reported Partner's Hypoactive Sexual Desire in Comparison with Conventional Risk Factors. Journal of Sexual Medicine, 2012, 9, 3227-3238.	0.6	15
296	Stable extramarital affairs are breaking the heart. Journal of Developmental and Physical Disabilities, 2012, 35, 11-17.	3.6	15
297	Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. Drug Safety, 2017, 40, 115-119.	3.2	15
298	Factors associated with the onset of major depressive disorder in adults with type 2 diabetes living in 12 different countries: results from the INTERPRET-DD prospective study. Epidemiology and Psychiatric Sciences, 2020, 29, e134.	3.9	15
299	Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 161, 108087.	2.8	15
300	Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. Journal of Endocrinological Investigation, 2012, 35, 915-20.	3.3	15
301	Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes. Journal of Endocrinological Investigation, 2006, 29, 619-624.	3.3	14
302	Is Metabolic Syndrome a Useless Category in Subjects with High Cardiovascular Risk? Results from a Cohort Study in Men with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 504-511.	0.6	14
303	Autologous Skin Fibroblast and Keratinocyte Grafts in the Treatment of Chronic Foot Ulcers in Aging Type 2 Diabetic Patients. Journal of the American Podiatric Medical Association, 2011, 101, 55-58.	0.3	14
304	Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study. Acta Diabetologica, 2012, 49, 179-184.	2.5	14
305	Targeting educational therapy for type 2 diabetes: identification of predictors of therapeutic success. Acta Diabetologica, 2013, 50, 309-317.	2.5	14
306	Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. Current Medical Research and Opinion, 2013, 29, 339-342.	1.9	14

#	Article	IF	CITATIONS
307	Gynecomastia in subjects with sexual dysfunction. Journal of Endocrinological Investigation, 2014, 37, 525-532.	3.3	14
308	Indexes of abdominal adiposity in patients with Type 2 diabetes. Journal of Endocrinological Investigation, 2004, 27, 535-540.	3.3	13
309	Seizures as the only clinical manifestation of reactive hypoglycemia: A case report. Journal of Endocrinological Investigation, 2005, 28, 940-941.	3.3	13
310	Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study. Advances in Therapy, 2011, 28, 1-18.	2.9	13
311	Lipid levels in obese and nonobese subjects as predictors of fasting and postload glucose metabolism. Journal of Clinical Lipidology, 2012, 6, 132-138.	1.5	13
312	Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 Diabetes. PLoS ONE, 2012, 7, e40074.	2.5	13
313	Impaired Masturbationâ€Induced Erections: A New Cardiovascular Risk Factor for Male Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 1100-1113.	0.6	13
314	Cardiovascular effects of basal insulins. Drug, Healthcare and Patient Safety, 2015, 7, 113.	2.5	13
315	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1071-1078.	2.6	13
316	Vascular and Chronological Age in Men With Erectile Dysfunction: A Longitudinal Study. Journal of Sexual Medicine, 2016, 13, 200-208.	0.6	13
317	Emotional eating and temperamental traits in Eating Disorders: A dimensional approach. Psychiatry Research, 2018, 264, 1-8.	3.3	13
318	Italian guidelines for the treatment of type 2 diabetes. Acta Diabetologica, 2022, 59, 579-622.	2.5	13
319	National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: Results from the FIBAR Study. Journal of Endocrinological Investigation, 2007, 30, 925-930.	3.3	12
320	Metabolic syndrome and pulse pressure. Diabetes, Obesity and Metabolism, 2007, 9, 600-602.	4.4	12
321	Glomerular hyperfiltration and metabolic syndrome: results from the Flrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetologica, 2009, 46, 191-196.	2.5	12
322	Periodontal disease and oral hygiene habits in a type 2 diabetic population. International Journal of Dental Hygiene, 2011, 9, 68-73.	1.9	12
323	Temperament and emotional eating: A crucial relationship in eating disorders. Psychiatry Research, 2015, 225, 452-457.	3.3	12
324	Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine, 2021, 74, 508-517.	2.3	12

#	Article	IF	CITATIONS
325	Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS). Acta Diabetologica, 2022, 59, 435-438.	2.5	12
326	Effectiveness of low arbohydrate diets for longâ€ŧerm weight loss in obese individuals: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2022, 24, 1458-1468.	4.4	12
327	Comparison among different insulin sensitivity indices in obese patients. Diabetic Medicine, 2003, 20, 462-466.	2.3	11
328	Fit and Motivated: Outcome Predictors in Patients Starting a Program for Lifestyle Change. Obesity Facts, 2013, 6, 279-287.	3.4	11
329	All-cause and cardiovascular mortality in a consecutive series of patients with diabetic foot osteomyelitis. Diabetes Research and Clinical Practice, 2017, 131, 12-17.	2.8	11
330	Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 155, 107808.	2.8	11
331	Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1027-1034.	2.6	11
332	Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinology, 2020, , .	1.1	11
333	Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. Asian Journal of Andrology, 2014, 16, 767.	1.6	11
334	Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. International Journal of Cardiology, 2008, 126, 247-251.	1.7	10
335	Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 646-649.	3.6	10
336	Resistin level in coronary artery disease and heart failure. Journal of Cardiovascular Medicine, 2013, 14, 150-157.	1.5	10
337	Vascular and Chronological Age in Subjects with Erectile Dysfunction: A Cross-Sectional Study. Journal of Sexual Medicine, 2015, 12, 2303-2312.	0.6	10
338	Echocardiographic findings in patients with eating disorders: AÂcase–control study. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 694-696.	2.6	10
339	Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetologica, 2017, 54, 411-413.	2.5	10
340	Combined continuous glucose monitoring and subcutaneous insulin infusion versus selfa \in monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2020, 22, 1286-1291.	4.4	10
341	Obesity as a risk factor for hospitalization in COronaVirus Disease-19 (COVID-19) patients: Analysis of the Tuscany regional database. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 769-773.	2.6	10
342	Italian guidelines for the treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 770-814.	2.6	10

#	Article	IF	Citations
343	Eating habits in elderly diabetic subjects: Assessment in the InCHIANTI Study. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 278-282.	2.6	9
344	Lack of Sexual Privacy Affects Psychological and Marital Domains of Male Sexual Dysfunction. Journal of Sexual Medicine, 2014, 11, 431-438.	0.6	9
345	Lower and higher-potency statins on glycemic control in type 2 diabetes: A retrospective cohort study. Diabetes Research and Clinical Practice, 2016, 120, 104-110.	2.8	9
346	Bringing the body of the iceberg to the surface: the Female Sexual Dysfunction Index-6 (FSDI-6) in the screening of female sexual dysfunction. Journal of Endocrinological Investigation, 2016, 39, 401-409.	3.3	9
347	Systematic Screening of Retinopathy in Diabetes (REaD Project): An Italian Implementation Campaign. European Journal of Ophthalmology, 2017, 27, 179-184.	1.3	9
348	A randomized, open-label, controlled trial to evaluate the antimicrobial and surgical effect of CO2 laser treatment in diabetic infected foot ulcers: DULCIS (diabetic ulcer, CO2 laser, and infections) study. Journal of Endocrinological Investigation, 2017, 40, 985-989.	3.3	9
349	Alternative treatment or alternative to treatment? A systematic review of randomized trials on homeopathic preparations for diabetes and obesity. Acta Diabetologica, 2019, 56, 241-243.	2.5	9
350	Association between resting energy expenditure, psychopathology and HPA-axis in eating disorders. World Journal of Clinical Cases, 2014, 2, 257.	0.8	9
351	Glucagon modulates proliferation and differentiation of human adipose precursors. Journal of Molecular Endocrinology, 2019, 63, 249-260.	2.5	9
352	Cardiovascular risk engines can help in selecting patients to be evaluated by dynamic penile color doppler ultrasound. Journal of Endocrinological Investigation, 2008, 31, 1058-1062.	3.3	8
353	Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?. Current Diabetes Reports, 2009, 9, 342-347.	4.2	8
354	Investigation on psychological symptoms improves ANDROTEST accuracy in predicting hypogonadism in subjects with sexual dysfunction. International Journal of Impotence Research, 2013, 25, 34-39.	1.8	8
355	Cardiovascular safety of insulin: Between realâ€world data and reality. Diabetes, Obesity and Metabolism, 2017, 19, 1201-1204.	4.4	8
356	Is cleaved glucagon-like peptide 1 really inactive? Effects of GLP-1(9-36) on human adipose stem cells. Molecular and Cellular Endocrinology, 2017, 439, 10-15.	3.2	8
357	A case of malignant insulinoma responsive to somatostatin analogs treatment. BMC Endocrine Disorders, 2018, 18, 98.	2.2	8
358	Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108115.	2.8	8
359	The use of insulin in elderly patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2011, 12, 2865-2881.	1.8	7
360	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Research and Care, 2015, 3, e000109.	2.8	7

#	Article	IF	Citations
361	CO2 laser for the treatment of diabetic foot ulcers with exposed bone. A consecutive series of type 2 diabetic patients. Journal of Endocrinological Investigation, 2017, 40, 819-822.	3.3	7
362	Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus. Antioxidants, 2020, 9, 233.	5.1	7
363	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 529-536.	2.6	7
364	Screening for diabetes in obese patients using the new diagnostic criteria. Diabetes Care, 1998, 21, 468-469.	8.6	6
365	Medium-term hypoglycaemic effects of two different oral formulations of gliclazide. Diabetic Medicine, 1999, 16, 618-619.	2.3	6
366	Comparison between 2 insulin sensitivity indexes in obese patients. Diabetes Care, 2000, 23, 1042-1043.	8.6	6
367	Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetologica, 2010, 47, 7-11.	2.5	6
368	GLP-1 receptor agonist-induced polyarthritis: a case report. Acta Diabetologica, 2013, 51, 673-4.	2.5	6
369	All roads bring to Rome: a different way for predicting success in the therapy of obesity through psychological features. Journal of Endocrinological Investigation, 2014, 37, 1187-1194.	3.3	6
370	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A metaâ€analysis from the <scp>GetGoal</scp> programme. Diabetes, Obesity and Metabolism, 2017, 19, 248-256.	4.4	6
371	Homeopathic Remedies in Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2020, 40, 269-275.	1.4	6
372	Glucose variability and periodontal disease in type 1 diabetes: a cross-sectional study—The "PAROdontopatia e DIAbete―(PARODIA) project. Acta Diabetologica, 2021, 58, 1367-1371.	2.5	6
373	Rosiglitazone and cardiovascular risk. New England Journal of Medicine, 2007, 357, 938; author reply 939-40.	27.0	6
374	Further data on the comparison between World Health Organization and American Diabetes Association diagnostic criteria DIAINF Study Group. Diabetes Care, 1999, 22, 1755-1757.	8.6	5
375	Prognostic value of dobutamine stress echocardiography in diabetic patients. International Journal of Cardiovascular Imaging, 2010, 26, 499-507.	1.5	5
376	Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?. International Journal of Cardiology, 2015, 184, 543-544.	1.7	5
377	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 375-377.	2.6	5
378	Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 71-76.	2.6	5

#	Article	IF	CITATIONS
379	ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. European Heart Journal Supplements, 2021, 23, C184-C195.	0.1	5
380	All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 511-514.	2.6	5
381	A simple ultrasound score for the identification of candidates to fine needle aspiration of thyroid nodules. Journal of Endocrinological Investigation, 2012, 35, 720-4.	3.3	5
382	Use of an Oxidized Regenerated Cellulose and Collagen Composite for Healing of Chronic Diabetic Foot Ulcers: A report of two cases. Diabetes Care, 2002, 25, 1892-1893.	8.6	4
383	Effect of lower diagnostic thresholds on estimates of prevalence of impaired fasting glucose (IFG). Diabetic Medicine, 2005, 22, 353-354.	2.3	4
384	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al Diabetes Care, 2007, 30, 193-194.	8.6	4
385	Glucagon-Like Peptide-1 and Diabetes 2012. Experimental Diabetes Research, 2012, 2012, 1-1.	3.8	4
386	The Eating Disorders Well Being Questionnaire (EDwell): a new measure of quality of life in eating disorders. Eating and Weight Disorders, 2013, 18, 11-22.	2.5	4
387	Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes. Scientific World Journal, The, 2013, 2013, 1-4.	2.1	4
388	Coronary artery disease screening in type II diabetic patients: Prognostic value of rest and stress echocardiography. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 18-23.	3.6	4
389	Assessing quality of life in severe obesity: development and psychometric properties of the ORWELL-R. Eating and Weight Disorders, 2016, 21, 277-288.	2.5	4
390	Adjustment of insulin doses when switching from glargine 100ÂU/ml or detemir to degludec: an observational study. Journal of Endocrinological Investigation, 2019, 42, 319-326.	3.3	4
391	Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6Âmonths of treatment. Acta Diabetologica, 2019, 56, 1231-1233.	2.5	4
392	Choosing the best algorithm among five thyroid nodule ultrasound scores: from performance to cytology sparingâ€"a single-center retrospective study in a large cohort. European Radiology, 2021, 31, 5689-5698.	4.5	4
393	Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 330-336.	2.6	4
394	Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study. Clinical Oral Investigations, 2022, 26, 3585-3591.	3.0	4
395	Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	4
396	Inaccuracy in meta-analysis on rosiglitazone and myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, e7-e8.	2.6	3

#	Article	IF	CITATIONS
397	False and true pre-treatment predictors of weight loss in obese patients starting a program for lifestyle change. Eating and Weight Disorders, 2014, 19, 489-494.	2.5	3
398	Is early measurement of glycated albumin and HbA1c useful for the prediction of treatment response in type 2 diabetes?. Acta Diabetologica, 2016, 53, 669-672.	2.5	3
399	Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 215-219.	2.6	3
400	The Florence Emotional Eating Drive (FEED): a validation study of a self-report questionnaire for emotional eating. Eating and Weight Disorders, 2021, , 1.	2.5	3
401	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	3.2	3
402	CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1195-1201.	2.6	3
403	Effects of antihypertensive treatments on incidence of diabetes: a case-control study. Journal of Endocrinological Investigation, 2012, 35, 135-8.	3.3	3
404	Major Amputation In Non-Healing Ulcers: Outcomes and Economic Issues. Data from a Cohort of Patients with Diabetic Foot Ulcers. International Journal of Lower Extremity Wounds, 2022, , 153473462210972.	1.1	3
405	Diabetes from Catecholamine Excess. Frontiers in Diabetes, 2014, , 44-51.	0.4	2
406	Is there a practical way of predicting therapeutic success in type 2 diabetes on the basis of psychological features? Development and validation of the Psychological Predictors of Therapeutic success in Diabetes (PPTD) questionnaire. Acta Diabetologica, 2014, 51, 133-140.	2.5	2
407	Lixisenatide: clinical profile and available evidence. Diabetes Management, 2014, 4, 71-84.	0.5	2
408	Motivational enhancement therapy in obese patients: A promising application. Obesity Research and Clinical Practice, 2015, 9, 536-538.	1.8	2
409	Association between different screening strategies for SARSâ€CoVâ€2 and deaths and severe disease in Italy. International Journal of Clinical Practice, 2021, 75, e13867.	1.7	2
410	RE: On the misuse of "weighted―composite scores: the scoring procedure of the FEED questionnaire does not indicate whether it is necessary to differentiate between the frequency of experiencing an emotion and the desire to eat in response to that emotion in the assessment of emotional eating. Eating and Weight Disorders, 2021, , 1.	2.5	2
411	Assessment of left ventricular global longitudinal strain in patients with type 2 diabetes: Relationship with microvascular damage and glycemic control. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 994-1000.	2.6	2
412	Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes. Journal of Receptor, Ligand and Channel Research, 0, , 105.	0.7	1
413	Left ventricular cavity obliteration during dobutamine stress echocardiography in diabetic patients. International Journal of Cardiovascular Imaging, 2012, 28, 1023-1033.	1.5	1
414	Comment on Ferrannini et al. Diabetes Care 2016;39:1108–1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115–1122. Diabetes Care, 2016, 39, e195-e195.	8.6	1

#	ARTICLE Reply to Eugenio Ventimiglia, Paolo Capogrosso, Walter Cazzaniga, Francesco Montorsi, and Andrea	IF	CITATIONS
415	Salonia's Letter to the Editor re: Giovanni Corona, Giulia Rastrelli, Abraham Morgentaler, Alessandra Sforza, Edoardo Mannucci, Mario Maggi. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017;72:1000–11. European	1.9	1
416	Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000263.	0.1	1
417	Retrospective Matched Case-Control Study on the Use of CO ₂ Laser for the Treatment of Nonhealing Diabetic Foot Ulcers: The DULCIS-2 (Diabetic ULcer, CO ₂ Laser, and Infections) Study. International Journal of Lower Extremity Wounds, 2022, 21, 471-476.	1.1	1
418	Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study. Diabetes Care, 2021, 44, e127-e128.	8.6	1
419	Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Endocrine Abstracts, 0, , .	0.0	1
420	[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]. Farmeconomia E Percorsi Terapeutici, 2016, 17, 19-27.	0.1	1
421	Online group lifestyle modification programs for obesity during the COVID-19 pandemic: The EDucation ONline (EDON) retrospective study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1317-1318.	2.6	1
422	Feasibility of Multiparametric Screening for Glucose Tolerance. Laboratory Medicine, 2006, 37, 352-357.	1.2	0
423	Is Basal Insulin Always the First Choice for Initiation of Insulin Therapy in Type 2 Diabetic Patients?. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 339-340.	1.2	0
424	Corrections to: " <i>The Journal of Sexual Medicine</i> 2010;7:2831–41.― Journal of Sexual Medicine, 2010, 7, 3803-3803.	0.6	0
425	The impossible return to the Garden of Eden: The ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, e35-e36.	2.6	0
426	Italian toasted bread (â€~bruschetta') should be carefully evaluated by people with type 1 diabetes. Acta Diabetologica, 2014, 51, 331-332.	2.5	0
427	Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
428	Reply to the "Letter to the Editor―Ma Z -G, Yuan Y-P, Zhang X, Tang Q-Z. SGLT1: A potential target for human ischemic and hypertrophic heart? Int J Cardiol (2017). International Journal of Cardiology, 2018, 257, 38.	1.7	0
429	Reply to Josef Finsterer"MELAS requires broad clinical and genetic work-up― Acta Diabetologica, 2019, 56, 1089-1090.	2.5	0
430	Reply to Gaertner, K. and Frass, M Acta Diabetologica, 2019, 56, 247-247.	2.5	0
431	Intestinal Hormones. , 2020, , 361-381.		0
432	Metformin in vitro and in vivo increases adenosine signalling in rabbit corpora cavernosa. Endocrine Abstracts, $0, \dots$	0.0	0

#	Article	IF	CITATIONS
433	Which antidiabetic drug indications are recommended for geriatric DM patients?. Journal of Gerontology and Geriatrics, 2021, 69, 276-281.	0.5	O
434	Reply to: Flaws in the meta-analysis of comparison between different types of exercise training in patients with type 2 diabetes mellitus: A letter to the editor. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	0